Botulinum toxin type A

Generic Name: Botulinum toxin type A

Brand Names: Botox, Botox Cosmetic, Dysport, Jeuveau, Xeomin, Nuceiva

Drug Type: Biotech

Chemical Formula: -

CAS Number: 93384-43-1

Unique Ingredient Identifier: 0A6JH35GMQ

Background: In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. With a wide variety of applications and favourable safety profile, Botulinum toxin A injection is a minimally invasive and promising treatment for cosmetic imperfections, muscle spasms, and other condit...

Indication: Botulinum toxin A is indicated for a variety of conditions, depending on the preparations. Cosmetically, it is used for the treatment of facial fine lines and wrinkles, specifically for upper facial rhytides, including forehead, lateral canthus, and glabellar lines.
...

Associated Conditions: Bladder pain, Blepharospasm, Cervical Dystonia, Chronic Migraine, Diabetic Neuropathies, Epicondylitis, Equinus deformity of foot, acquired, Facial Skin Wrinkles, Glabellar Frown Lines (GL), Lower Limb Spasticity, Myofascial Pain Syndrome, Neurogenic Detrusor Overactivity, Neurogenic Thoracic Outlet Syndrome, Overactive Bladder Syndrome (OABS), Post Stroke Pain, Postherpetic Neuralgia, Sialorrhea, Spasticity, Spinal Cord Injuries, Strabismus, TMJ Disorders, Trigeminal Neuralgia (TN), Upper Limb Spasticity, Urinary Incontinence (UI), Hypertonicity disorders of the 7th nerve, Moderate Glabellar Frown Lines (GL), Severe Glabellar Frown Lines (GL), Severe axillary hyperhidrosis

Associated Therapies: -

Clinical Trials

Botulinum Toxin Treatment for Localized Vitiligo

Phase 4

Completed

Conditions: Vitiligo

Interventions: Drug: Botulinum toxin A

First Posted Date: 2010-01-18

Last Posted Date: 2010-01-18

Lead Sponsor: King Saud University

Target Recruit Count: 10

Registration Number: NCT01051687

Locations: 🇸🇦
King Khalid University Hospital, Riyadh, Saudi Arabia

Botulism Toxin Injection as a Treatment for Arthritis of the Basal Thumb Joint

Phase 4

Terminated

Conditions: Arthritis Multiple Joint

Interventions: Drug: Steroid - Triamcinolone Acetonide
Drug: Lidocaine
Drug: Botulinum Toxin Type A

First Posted Date: 2010-01-11

Last Posted Date: 2017-10-06

Lead Sponsor: University of Missouri-Columbia

Target Recruit Count: 8

Registration Number: NCT01045694

Locations: 🇺🇸
University of Missouri, Columbia, Missouri, United States

The Efficacy of Botulinum Toxin in Disabling Multiple Sclerosis (MS) Tremor

Phase 3

Completed

Conditions: Tremor
Multiple Sclerosis

Interventions: Drug: Botulinum Toxin Type A

First Posted Date: 2009-11-23

Last Posted Date: 2015-05-12

Lead Sponsor: Melbourne Health

Target Recruit Count: 30

Registration Number: NCT01018485

Locations: 🇦🇺
Melbourne Health, Melbourne, Victoria, Australia

Quality of Life and Self-esteem After Botox® Injections in Depressed and Non-depressed Patients

Phase 4

Completed

Conditions: Depression
Quality of Life

Interventions: Drug: Botulinum Toxin Type A

First Posted Date: 2009-10-29

Last Posted Date: 2021-01-26

Lead Sponsor: Brazilan Center for Studies in Dermatology

Target Recruit Count: 50

Registration Number: NCT01004042

Locations: 🇧🇷
Brazilian Center for Studies in Dermatology, Porto Alegre, Rio Grande Do Sul, Brazil

The Comparison Study of Intralesional Botulinum Toxin A and Corticosteroid Injection for Alopecia Areata

Not Applicable

Conditions: Alopecia Areata

Interventions: Drug: Botulinum toxin type A
Drug: Triamcinolone acetonide

First Posted Date: 2009-10-22

Last Posted Date: 2012-08-07

Lead Sponsor: Siriraj Hospital

Target Recruit Count: 20

Registration Number: NCT00999869

Locations: 🇹🇭
Department of Dermatology, Faculty of medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
🇹🇭
Siriraj hospital, Bangkok, Thailand